article thumbnail

Smileyscope Receives FDA Clearance for First-Ever VR Analgesic

HIT Consultant

Food and Drug Administration (FDA) for its Smileyscope™ Therapy system. – The FDA clearance marks Smileyscope as the first and only VR Analgesic™ available in the US. billion USD by 2030. “We were thrilled to receive this FDA Class II clearance. The Digital Therapeutics market is projected to reach 32.5

FDA 97
article thumbnail

Exo® Launches FDA-Cleared AI on Exo Iris™ to Address Heart Failure

HIT Consultant

What You Should Know: Exo® (pronounced “echo”) , a medical imaging software and devices company, today announced its FDA-cleared cardiac and lung artificial intelligence (AI) applications are now available on Exo Iris™, Exo’s high-performance handheld ultrasound device.

FDA 94
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Dexcom Ventures Invests in MedCrypt’s Medical Device Cybersecurity Platform

HIT Consultant

billion and is expected to grow 28% by 2030. The Food and Drug Administration (FDA) tracked the potential cybersecurity risks associated with both insulin and glucose monitors, noting these devices need to be reliable and trustworthy as users are pairing them with other system components such as smartphones.

FDA 97
article thumbnail

Tytocare is Making Home Medical Care Easier and More Accurate

Healthcare IT Today

Their offering includes: An FDA-cleared handheld solution for remote physical examinations and diagnosis. billion USD by 2030 according to a study by Precedence Research. TytoCare , a virtual care company, recently launched its Home Smart Clinic that enables primary care from home. billion USD in 2021 to $62.1

FDA 107
article thumbnail

Evolution: Why It’s Time to Look at Digital Health ROI Differently

HIT Consultant

Shubs Upadhyay, Director of Medical Quality, Ada Health Lucy Orr-Ewing, Chief of Staff and Head of Policy, Coalition for Health AI (CHAI) As the digital health market continues to expand—projected to grow from nearly $250 billion in 2023 to over $815 billion by 2030 —it’s essential to reassess how we measure its success.

ADA 98
article thumbnail

The Self-Prescribing Consumer: DIY Comes to Prescriptions via GLP-1s, the OPill, and Dexcom’s CGM

Health Populi

The first continuous-glucose monitor that does not require a prescription was approved by the FDA on March 5, 2024. Jeff Shuren, MD, JD, director of the FDA’s Center for Devices and Radiological Health, asserted in the FDA approval announcement, CGMs can be a powerful tool to help monitor blood glucose. .”

FDA 83
article thumbnail

Dexom Ventures Invests in MedCrypt’s Medical Device Cybersecurity Platform

HIT Consultant

billion and is expected to grow 28% by 2030. The Food and Drug Administration (FDA) tracked the potential cybersecurity risks associated with both insulin and glucose monitors, noting these devices need to be reliable and trustworthy as users are pairing them with other system components such as smartphones.

FDA 52